Case Study: Milestone Therapeutics amplifies pivotal cardiology trial data with JPA Health

Milestone Therapeutics amplifies 5 media interviews with JPA Health

Milestone Therapeutics faced the challenge of raising awareness for its investigational therapy etripamil at the crowded American Heart Association (AHA) Annual Scientific Session. The company needed to secure significant media coverage for its positive Phase 3 clinical trial data ahead of a planned FDA submission. JPA Health was tasked with developing a strategy to cut through the noise of the busy medical congress.

JPA Health implemented a targeted media strategy that included embargoed outreach to key reporters, offering them a virtual roundtable with Milestone spokespeople to discuss the data ahead of its release. This approach was supplemented with ongoing outreach to a broader list of media outlets. The solution successfully generated positive coverage in influential outlets like STAT News and FierceBiotech, resulting in 5 media interviews, 20 original news articles, and a potential audience reach of 100 million people.

Milestone Therapeutics